Canaccord Genuity Maintains a 'Buy' on Optimer Pharmaceuticals (OPTR); Q3/11 Update: Dificid Sales Surpass Expectations
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Price: $12.78 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target of $20.00.
Canaccord analyst, George Farmer, says, "DIFICID Q3 net sales of $10.6M (~4.5M inventory build), representing 4,335 shipped treatments, beat our Street-high estimate/consensus of $7.2M/$5.57M. Of these, $7M was sold through retail pharmacies (RP) and long-term care facilities (LTCF), accounting for 2,505 treatments. Aug./Sep. shipped treatments (884/1,140) to RP and LTCF increased by 29%, indicative of a strong launch and continued growth potential, in our view. At this trajectory, management projects reaching breakeven in the US within three years. We increase our 2011 DIFICID sales estimate to $27M from $17.3M and LPS estimate to ($0.79) from ($0.22) on increased expense estimates."
For more ratings news on Optimer Pharmaceuticals click here and for the rating history of Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $14.64 yesterday.
Canaccord analyst, George Farmer, says, "DIFICID Q3 net sales of $10.6M (~4.5M inventory build), representing 4,335 shipped treatments, beat our Street-high estimate/consensus of $7.2M/$5.57M. Of these, $7M was sold through retail pharmacies (RP) and long-term care facilities (LTCF), accounting for 2,505 treatments. Aug./Sep. shipped treatments (884/1,140) to RP and LTCF increased by 29%, indicative of a strong launch and continued growth potential, in our view. At this trajectory, management projects reaching breakeven in the US within three years. We increase our 2011 DIFICID sales estimate to $27M from $17.3M and LPS estimate to ($0.79) from ($0.22) on increased expense estimates."
For more ratings news on Optimer Pharmaceuticals click here and for the rating history of Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $14.64 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades AAC Technologies Holdings Inc. (2018:HK) (AACAY) to Neutral
- Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'
- HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
